Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca opens research center as UK builds science hub

11/23/2021 | 02:02pm EST

LONDON (AP) — Prince Charles praised Cambridge as a center of scientific collaboration Tuesday as the pharmaceutical company AstraZeneca opened a 1 billion-pound ($1.34 billion) research center, hoping to build on work in developing one of the first COVID-19 vaccines.

The 19,000 square-meter (more than 200,000 square-foot) complex near the University of Cambridge will house more than 2,200 research scientists. It joins a cluster of businesses seeking to make Cambridge a hub for life sciences research similar to what California’s Silicon Valley is for the technology industry.

“Having myself studied at Cambridge ... over 50 years ago now, one of the things which I have always found so special about this city is how it attracts the meeting of minds, sparks unique cross-disciplinary conversations and nurtures collaboration and ingenuity,'' Charles said at the official opening.

The Cambridge life sciences cluster includes 631 companies that employ almost 21,000 people and generate annual revenue of 7 billion pounds, according to Cambridge Ahead, which promotes business development in the city.

AstraZeneca worked with Oxford University to develop one of the first COVID-19 vaccines approved by regulators in the U.K., European Union and other countries. The company and its licensing partners have delivered more than 1.5 billion vaccine doses around the world after pledging to sell it on a non-profit basis during the pandemic.

AstraZeneca said last week that it planned to start to sell the vaccine at a “modest” profit, though it would continue to offer it to developing countries at cost.

AstraZeneca also plans to ask the U.S. Food and Drug Administration to approve the vaccine.

Follow all AP stories on the pandemic at https://apnews.com/hub/coronavirus-pandemic.

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about ASTRAZENECA PLC
07:00aCORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with H..
BU
04:37aEnhertu granted Priority Review in the US for patients with HER2-positive metastatic br..
AQ
03:01aCline Scientific extends collaboration agreement with AstraZeneca
AQ
02:40aAstraZeneca's Enhertu Granted Priority Review by US Regulator
DJ
02:31aJens Lindberg takes office as CEO of Medivir on January 24
AQ
02:23aAstraZeneca-Daiichi Sankyo's Breast Cancer Drug Accepted For Priority Review in US
MT
02:06aProsecution Takes Over Case of 8 Medics Pinned for Misusing Covid-19 Vaccines
AQ
01:09aIsrael Reopens Borders To Entry By Foreign Nationals
AQ
01/14EMA lists rare spinal condition as side effect of AstraZeneca's COVID-19 shot
RE
01/14European Medicines Agency Asks AstraZeneca, Johnson & Johnson To Add Spinal Inflammatio..
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 079 M - -
Net income 2021 2 716 M - -
Net Debt 2021 24 814 M - -
P/E ratio 2021 54,7x
Yield 2021 2,35%
Capitalization 185 B 186 B -
EV / Sales 2021 5,83x
EV / Sales 2022 4,78x
Nbr of Employees 76 100
Free-Float -
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 119,68 $
Average target price 138,50 $
Spread / Average Target 15,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC-1.54%181 019
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317